论文部分内容阅读
目的探究晚期乳腺癌行吉西他滨、长春瑞滨与顺铂联合治疗的疗效与不良反应。方法回顾性分析2013年1月至2015年7月于江门市中心医院收治的70例晚期乳腺癌患者的临床资料,根据治疗方案分为两组,每组35例,对照组使用的是吉西他滨与顺铂联合治疗方式,观察组使用的是长春瑞滨与顺铂联合治疗方式,对资料进行对比和分析。结果观察组不良反应总发生率28.57%,显著低于对照组的65.71%(P<0.05)。结论晚期乳腺癌患者行吉西他滨、长春瑞滨与顺铂联合治疗的效果显著,均可有效缩小病灶,缓解病情,且长春瑞滨与顺铂联合治疗的不良反应较少,值得临床推广。
Objective To investigate the efficacy and adverse reactions of gemcitabine, vinorelbine and cisplatin in the treatment of advanced breast cancer. Methods The clinical data of 70 patients with advanced breast cancer who were admitted to Jiangmen Central Hospital from January 2013 to July 2015 were retrospectively analyzed. According to the treatment plan, they were divided into two groups of 35 cases each. Gemcitabine and Cisplatin combination therapy, the observation group is the combination of vinorelbine and cisplatin treatment, the data were compared and analyzed. Results The total incidence of adverse reactions in observation group was 28.57%, which was significantly lower than that in control group (65.71%, P <0.05). Conclusions The combination of gemcitabine, vinorelbine and cisplatin is effective in patients with advanced breast cancer. All of them can effectively reduce the size of the lesion and relieve the disease. There are few adverse reactions in the combination of vinorelbine and cisplatin, which is worthy of clinical promotion.